Trial Information

Summary: If you are aged 18 to 55 and have allergic asthma, you may qualify for a research study.

A 26 week, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the effect of Xolair(omalizumab) on improving the tolerability of specific immunotherapy in patients with persistent allergic asthma.

If you are aged 18 to 55 and have allergic asthma, you may qualify for a research study. Qualified participants will receive FDA approved study medication and study-related exams at no cost and reimbursement for time and travel. To learn about asthma research, call Toledo Center for Clinical Research at:

Contact:

Melanie Schell, Coordinator
Toledo Center for Clinical Research (TCCR)
5860 W. Alexis Rd.
Suite B
Sylvania, OH 43560
Telephone: 419-885-5163
Fax: 419-885-1758
Email:

Profile Page: Toledo Center for Clinical Research (TCCR), Sylvania, OH

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:43 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA